Skip to content

13F-HR filed by Ally Bridge Group (NY) LLC

Ally Bridge Group (NY) LLC filed this 13F-HR for the quarter ended 2020-12-31, filed 2021-02-16, with 30 holding rows worth $583,531,000.

Accession
0000950123-21-002363
Filed
2021-02-16
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q4 2020

A holdings report, 30 entries on the cover page, a total value of $583,531,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $583,531,000 with VALUE read as thousands by filing date, 13F file number 028-20834. The quarter's positions are built on this report. The resolved quarter.

Other managers

  • included managerFan Yu

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
SPDR SERIES TRUST78464A950PUT1,100,000$154,858,000thousands by filing dateput
MEDAVAIL HOLDINGS INC58406B103COM2,920,780$43,958,000thousands by filing date
ATEA PHARMACEUTICALS INC04683R106COMMON STOCK1,016,688$42,477,000thousands by filing date
SAREPTA THERAPEUTICS INC803607900COM238,600$40,679,000thousands by filing datecall
CEREVEL THERAPEUTICS HLDNG I15678U128COM1,767,440$29,304,000thousands by filing date
SYROS PHARMACEUTICALS INC87184Q107COM2,642,500$28,671,000thousands by filing date
FATE THERAPEUTICS INC31189P102COM260,000$23,642,000thousands by filing date
NATERA INC COM632307104Stock188,000$18,710,000thousands by filing date
COGENT BIOSCIENCES INC19240Q201COM1,622,591$18,222,000thousands by filing date
IOVANCE BIOTHERAPEUTICS INC462260100COM360,000$16,704,000thousands by filing date
REPLIGEN CORP COM759916109Stock82,500$15,809,000thousands by filing date
CASTLE BIOSCIENCES INC14843C105COMMON STOCK210,000$14,102,000thousands by filing date
ORIC PHARMACEUTICALS INC68622P109COM413,061$13,982,000thousands by filing date
PULMONX CORP745848101COM199,122$13,743,000thousands by filing date
APELLIS PHARMACEUTICALS INC03753U106COM230,000$13,156,000thousands by filing date
INTELLIA THERAPEUTICS INC45826J105COM225,000$12,240,000thousands by filing date
AURINIA PHARMACEUTICALS INC COM05156V102Stock858,032$11,867,000thousands by filing date
ITEOS THERAPEUTICS INC46565G104COM322,794$10,917,000thousands by filing date
ITAMAR MED LTD SPONSORED ADS465437101ADR501,964$9,969,000thousands by filing date
ARVINAS INC04335A105COM100,000$8,493,000thousands by filing date
FREELINE THERAPEUTICS HLDGS35655L107SPONSORED ADS425,000$7,761,000thousands by filing date
VIR BIOTECHNOLOGY INC92764N102COM275,000$7,365,000thousands by filing date
4D MOLECULAR THERAPEUTICS INC COM35104E100Stock150,000$6,218,000thousands by filing date
APTOSE BIOSCIENCES INC COM03835T200Stock1,409,150$6,172,000thousands by filing date
ARS PHARMACEUTICALS INC82835W108COM128,572$5,958,000thousands by filing date
CHINOOK THERAPEUTICS INC16961L106COM199,600$3,166,000thousands by filing date
ORCHARD THERAPEUTICS PLC68570P101ADR547,427$2,365,000thousands by filing date
ONCTERNAL THERAPEUTICS INC68236P107COM300,000$1,470,000thousands by filing date
ESSA PHARMA INC29668H708COM NEW78,185$933,000thousands by filing date
NANOSTRING TECHNOLOGIES INC63009R109COM9,277$620,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0000950123-21-002363this filing2021-02-16acceptance time not in the bulk data set